Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and delta opioid systems

Journal of Neurochemistry

Volumn 124, Issue 6, 2013, Pages 808-820

  Blume, Lawrence C ^a   Bass, Caroline E ^a,c   Childers, Steven R ^a   Dalton, George D ^a   Roberts, David C S ^a   Richardson, Jasmine M ^a,d   Xiao, Ruoyu ^a   Selley, Dana E ^b   Howlett, Allyn C ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d CAMPBELL UNIVERSITY   (United States)

Author keywords

basal ganglia; cannabinoid receptor; enkephalin; gene expression; medium spiny neurons; mesolimbic dopamine pathway

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR INTERACTING PROTEIN 1A; DELTA OPIATE RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PRODYNORPHIN; PROENKEPHALIN; REGULATOR PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN; CNRIP1 PROTEIN, RAT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; STRIATE CORTEX; ANIMAL; BIOSYNTHESIS; CORPUS STRIATUM; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; METHODOLOGY; MOUSE; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARRIER PROTEINS; CORPUS STRIATUM; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID, DELTA;

MLCS; MLOWN;

EID: 84874674270     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12139     Document Type: Article

References (57)

1. Andersson M., Terasmaa A., Fuxe K., and, Stromberg I., (2005) Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia. J. Neurosci. Res. 82, 264-272.
2. Blazquez C., Chiarlone A., Sagredo O., et al,. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119-136.
3. Blume L. C., Bass C. E., Dalton G. D., Selley D. E., and, Howlett A. C., (2010) Cannabinoid receptor interacting protein (CRIP) 1a: signal transduction and epigenetic phenomena. ICRS Symp. Cannabinoids 20, P3-P30.
4. Brady L. S., Herkenham M., Rothman R. B., Partilla J. S., Konig M., Zimmer A. M., and, Zimmer A., (1999) Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. Brain Res. Mol. Brain Res. 68, 193-197.
5. Cabral G. A., and, Marciano-Cabral F., (2005) Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 78, 1192-1197.
6. Centonze D., Battista N., Rossi S., Mercuri N. B., Finazzi-Agro A., Bernardi G., Calabresi P., and, Maccarrone M., (2004) A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal GABAergic transmission. Neuropsychopharmacology 29, 1488-1497.
7. Crespo I., de Gomez H., and, R. Rodriguez de F. F., and, Navarro M., (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 54, 219-225.
8. Crunelle C. L., van de Giessen E., Schulz S., Vanderschuren L. J., de B. K., van den Brink W., and, Booij J,. (2011) Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addict. Biol. doi: 10.1111/j.1369-1600.2011.00369.x
9. De B. P., Heguy A., Hackett N. R., Ferris B., Leopold P. L., Lee J., Pierre L., Gao G., Wilson J. M., and, Crystal R. G., (2006) High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol. Ther. 13, 67-76.
10. Elphick M. R., Wallis K. T., Liu Y., Lewis D. L., and, Egertova, (2004) Localization of the CB1 cannabinoid receptor interacting protein (CRIP1a) in the brain. ICRS Symp. Cannabinoids 14, 19.
11. Fernandez-Ruiz J., (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 156, 1029-1040.
12. Fernandez-Ruiz J., Hernandez M., and, Ramos J. A., (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e72-e91.
13. Gao G. P., Alvira M. R., Wang L., Calcedo R., Johnston J., and, Wilson J. M., (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99, 11854-11859.
14. Gerald T. M., Ward G. R., Howlett A. C., and, Franklin S. O., (2006) CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression. Brain Res. 1093, 20-24.
15. Gerdeman G. L., Ronesi J., and, Lovinger D. M., (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5, 446-451.
16. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Jr, and, Sibley D. R., (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
17. Glass M., and, Felder C. C., (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327-5333.
18. Glass M., Dragunow M., and, Faull R. L., (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505-519.
19. Herkenham M., Lynn A. B., De Costa B. R., and, Richfield E. K., (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267-274.
20. Hermann H., Marsicano G., and, Lutz B., (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109, 451-460.
21. Houchi H., Babovic D., Pierrefiche O., Ledent C., Daoust M., and, Naassila M., (2005) CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30, 339-349.
22. Hu S. S., Arnold A., Hutchens J. M., Radicke J., Cravatt B. F., Wager-Miller J., Mackie K., and, Straiker A., (2010) Architecture of cannabinoid signaling in mouse retina. J. Comp. Neurol. 518, 3848-3866.
23. Ito D., Tanaka K., Suzuki S., Dembo T., and, Fukuuchi Y., (2001) Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 32, 1208-1215.
24. Jarrahian A., Watts V. J., and, Barker E. L., (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 308, 880-886.
25. Kearn C. S., (2004) Immunofluorescent mapping of cannabinoid CB1 and dopamine D2 receptors in the mouse brain. LI-COR Biosci, Application Notes.
26. Kearn C. S., Blake-Palmer K., Daniel E., Mackie K., and, Glass M., (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 67, 1697-1704.
27. Kilkenny C., Browne W. J., Cuthill I. C., Emerson M., and, Altman D. G., (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J. Pharmacol. Pharmacother. 1, 94-99.
28. Klein T. W., Newton C., Larsen K., Lu L., Perkins I., Nong L., and, Friedman H., (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496.
29. Lim G., Sung B., Ji R. R., and, Mao J., (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105, 275-283.
30. Lovinger D. M., (2010) Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 58, 951-961.
31. Ludanyi A., Eross L., Czirjak S., Vajda J., Halasz P., Watanabe M., Palkovits M., Magloczky Z., Freund T. F., and, Katona I., (2008) Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 28, 2976-2990.
32. Mackie K,. (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. Vol. 168, 299-325.
33. Mailleux P., and, Vanderhaeghen J. J., (1992) Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 148, 173-176.
34. Marcellino D., Carriba P., Filip M., et al,. (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. a combined neurochemical and behavioral analysis. Neuropharmacology 54, 815-823.
35. Martin A. B., Fernandez-Espejo E., Ferrer B., Gorriti M. A., Bilbao A., Navarro M., de Rodriguez F., and, F. and Moratalla R., (2008) Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33, 1667-1679.
36. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., and, Freund T. F., (2006) Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137, 337-361.
37. McBride J. L., Boudreau R. L., Harper S. Q., et al,. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl Acad. Sci. USA 105, 5868-5873.
38. Meschler J. P., and, Howlett A. C., (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40, 918-926.
39. Niehaus J. L., Liu Y., Wallis K. T., et al,. (2007) CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Mol. Pharmacol. 72, 1557-1566.
40. Paxinos G., and, Watson C., (1997) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
41. Pickel V. M., Chan J., Kearn C. S., and, Mackie K., (2006) Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens. J. Comp. Neurol. 495, 299-313.
42. Przybyla J. A., and, Watts V. J., (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J. Pharmacol. Exp. Ther. 332, 710-719.
43. Sadri-Vakili G., Kumaresan V., Schmidt H. D., et al,. (2010) Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. J. Neurosci. 30, 11735-11744.
44. Sanudo-Pena M. C., Tsou K., and, Walker J. M., (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65, 703-713.
45. Sheng W. S., Hu S., Min X., Cabral G. A., Lokensgard J. R., and, Peterson P. K., (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219.
46. Shi X., and, McGinty J. F., (2006) Extracellular signal-regulated mitogen-activated protein kinase inhibitors decrease amphetamine-induced behavior and neuropeptide gene expression in the striatum. Neuroscience 138, 1289-1298.
47. Sim L. J., Selley D. E., and, Childers S. R., (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc. Natl Acad. Sci. USA 92, 7242-7246.
48. Smith M. E., and, Eng L. F., (1987) Glial fibrillary acidic protein in chronic relapsing experimental allergic encephalomyelitis in SJL/J mice. J. Neurosci. Res. 18, 203-208.
49. Smith Y., and, Villalba R., (2008) Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov. Disord. 23 (Suppl 3), S534-S547.
50. van der Stelt M., and, DiMarzo V., (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480, 133-150.
51. Szabo B., Dorner L., Pfreundtner C., Norenberg W., and, Starke K., (1998) Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85, 395-403.
52. 2+/calmodulin-dependent protein kinase II pathways. J. Neurochem. 83, 784-796.
53. Tepper J. M., Abercrombie E. D., and, Bolam J. P., (2007) Basal ganglia macrocircuits. Prog. Brain Res. 160, 3-7.
54. Thanos P. K., Gopez V., Delis F., Michaelides M., Grandy D. K., Wang G. J., Kunos G., and, Volkow N. D., (2011) Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption. Alcohol. Clin. Exp. Res. 35, 19-27.
55. Van Waes V., Beverley J. A., Siman H., Tseng K. Y., and, Steiner H., (2012) CB1 Cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front. Pharmacol. 3, 21.
56. Warnault V., Houchi H., Barbier E., Pierrefiche O., Vilpoux C., Ledent C., Daoust M., and, Naassila M., (2007) The lack of CB1 receptors prevents neuroadapatations of both NMDA and GABA(A) receptors after chronic ethanol exposure. J. Neurochem. 102, 741-752.
57. Xiao X., Li J., and, Samulski R. J., (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232.